Asthma Clinical Trials

404 recruiting

Asthma Trials at a Glance

428 actively recruiting trials for asthma are listed on ClinicalTrialsFinder across 6 cities in 65 countries. The largest study group is Not Applicable with 130 trials, with the heaviest enrollment activity in Miami, Boston, and London. Lead sponsors running asthma studies include AstraZeneca, University of Colorado, Denver, and Chinese University of Hong Kong.

Treatments under study

Understanding Asthma Clinical Trials

Omalizumab (Xolair), approved in 2003 after clinical trials demonstrated its ability to reduce severe asthma attacks by targeting IgE antibodies, ushered in the era of biologic therapy for asthma. Subsequent trials delivered dupilumab, mepolizumab, benralizumab, and tezepelumab — each targeting different inflammatory pathways and collectively transforming the management of severe asthma. These breakthroughs were only possible through clinical trial participation, and ongoing trials are now tackling remaining challenges including non-eosinophilic severe asthma, asthma remission, and reducing dependence on oral corticosteroids.

Why Consider a Clinical Trial?

For people with mild or well-controlled asthma, standard inhalers and medications are generally effective. But approximately 5-10% of asthma patients have severe disease that is not adequately controlled despite high-dose inhaled corticosteroids and long-acting bronchodilators. These patients experience frequent exacerbations, emergency department visits, and hospitalizations, and many rely on repeated courses of oral corticosteroids that carry serious long-term side effects. Clinical trials for severe asthma offer access to therapies that may provide better control while reducing steroid dependence. Even within severe asthma, the disease is not uniform. Researchers now recognize distinct endotypes — subtypes defined by underlying biology — including eosinophilic asthma, allergic asthma, and non-type 2 asthma. While multiple biologic options exist for eosinophilic and allergic subtypes, patients with non-type 2 inflammation have far fewer treatment options, and this is an area of intense clinical trial activity. Trials are also studying whether biologics can be used earlier in the disease course, whether they can achieve true asthma remission (complete absence of symptoms and inflammation), and how to optimize treatment for patients who have not responded to currently available biologics.

Frequently Asked Questions

Common questions about Asthma clinical trials

Not necessarily. While many biologic trials focus on severe asthma, there are also trials for moderate asthma, exercise-induced asthma, and newly diagnosed asthma. Some trials study prevention strategies in children at high risk of developing asthma. The eligibility criteria vary widely by study.

Most asthma trials do not require you to stop your controller medications (inhaled corticosteroids and long-acting bronchodilators). However, some trials may include a steroid reduction phase where your inhaled steroid dose is gradually lowered to see if the study drug maintains control independently. You will always have access to your rescue inhaler.

Trials have safety protocols specifically designed for patients with frequent exacerbations. These include regular lung function monitoring, 24-hour contact with the study team, and clear guidelines for when to seek emergency care. If your asthma worsens significantly, the trial protocol will have a predefined plan, which may include rescue medication or withdrawal from the study.

Most asthma trials require spirometry, a breathing test that measures how much air you can exhale and how quickly. You will typically need to demonstrate reversibility — meaning your lung function improves after using a bronchodilator. Some trials also require FeNO testing, methacholine challenge tests, or peak flow monitoring at home.

Yes. Pediatric asthma trials are available, and they include additional safety protections and age-appropriate study designs. Trials for children are particularly important because asthma medications approved for adults cannot always be assumed to work the same way in children. Pediatric allergists and pulmonologists at academic centers are the best source for finding these trials.

Showing 120 of 428 trials

Recruiting

Personalized Environment and Genes Study

AsthmaDiabetesHeart Disease
National Institute of Environmental Health Sciences (NIEHS)25,000 enrolled1 locationNCT00341237
Recruiting

ReAl-woRld Evaluation of tEzepelumab for Chronic rhinoSinusitis With Nasal Polyps in Russia

AsthmaChronic Rhinosinusitis With Nasal Polyps (CRSwNP)
AstraZeneca110 enrolled9 locationsNCT07399665
Recruiting
Phase 3

Evaluating the Efficacy and Safety of PT027 Compared With PT007 Administered As Needed in Participants 12 to < 18 Years of Age With Asthma

Asthma
AstraZeneca440 enrolled135 locationsNCT06307665
Recruiting
Phase 3

A Study to Investigate the Efficacy and Safety of Tezepelumab Compared With Placebo in Children 5 to < 12 Years Old With Severe Asthma

Asthma
AstraZeneca231 enrolled143 locationsNCT06023589
Recruiting

PROPULSION SANTE: Inflammometry to Improve the Diagnostic Trajectory in Situations of Suspected Asthma in Children and Adults

AsthmaInflammationAsthma in Children
Université de Sherbrooke1,500 enrolled3 locationsNCT06981169
Recruiting
Phase 3

A Phase III Study of CM326 in Subjects With Moderate to Severe Asthma

Moderate to Severe Asthma
CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.230 enrolled1 locationNCT07372287
Recruiting

Evaluation of Ventilation Defects Downstream of Mucus Plugs in Patients With Severe Asthma

Severe Asthma
University of Kansas Medical Center5 enrolled1 locationNCT06985225
Recruiting

International Severe Asthma Registry: Canadian Cohort

Severe Asthma
University of British Columbia714 enrolled12 locationsNCT04045587
Recruiting
Phase 3

A Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents With Severe Uncontrolled Asthma (SOLAIRIA-1)

Severe Asthma
Generate Biomedicines786 enrolled27 locationsNCT07276724
Recruiting

Severe Asthma Network Italy

Severe Asthma
Società Italiana di Allergologia, Asma e Immunologia Clinica5,000 enrolled1 locationNCT06625216
Recruiting
Not Applicable

Role of "Asthma School" in Disease Management

Asthma
Istituti Clinici Scientifici Maugeri SpA92 enrolled1 locationNCT04442646
Recruiting
Not Applicable

Promoting Asthma Management Guidelines With Technology-Based Intervention and Care Coordination in Clinics and Schools

Asthma in Children
Montefiore Medical Center420 enrolled1 locationNCT07224061
Recruiting

Role of Genetic Factors in the Development of Lung Disease

AsthmaCystic FibrosisPulmonary Fibrosis+2 more
National Heart, Lung, and Blood Institute (NHLBI)3,500 enrolled2 locationsNCT00001532
Recruiting
Phase 2

Rademikibart Add-on Treatment of an Acute Asthma Exacerbation (Seabreeze STAT Asthma)

Asthma Acute
Connect Biopharm LLC160 enrolled52 locationsNCT06940141
Recruiting
Phase 1

A Study to Investigate How Budesonide and Formoterol Move Through the Body (Pharmacokinetics) When Delivered With Different Devices in Participants Aged 4 to Less Than 12 Years Old With Asthma

Asthma
AstraZeneca12 enrolled6 locationsNCT07433569
Recruiting
Phase 3

Depemokimab Asthma Imaging and Bronchoscopy Sub-Study

Asthma
GlaxoSmithKline150 enrolled43 locationsNCT06979323
Recruiting
Phase 4

Efficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Adolescent and Adult Patients With Uncontrolled Asthma

Asthma
Regeneron Pharmaceuticals250 enrolled84 locationsNCT06572228
Recruiting
Phase 2

A Study of KT-621 Administered Orally to Adult Participants With Moderate to Severe Eosinophilic Asthma

Eosinophilic Asthma
Kymera Therapeutics, Inc.264 enrolled17 locationsNCT07323654
Recruiting
Phase 3

Phase 3b Study in Patients With Severe Asthma Treated With Tezepelumab

Severe Asthma
AstraZeneca400 enrolled76 locationsNCT07363642
Recruiting

Mechanistic Insights From Bronchoscopy Airway Samples

Asthma
University of California, San Francisco24 enrolled1 locationNCT06105710